AFP and hepatocellular carcinoma: Our analysis shows that the achievement of 3‐year survival time in patients with hepatitis B‐related HCC initially treated with TACE was associated with a higher BMI, lower AST, shorter APTT, lower AFP, antivirus treatment, smaller tumor size, solitary tumor, and the absence of vascular invasion.